2. Immunology/Inflammation
  3. CD74 MHC
  4. PADRE peptide

PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

PADRE peptide

PADRE peptide Chemical Structure

CAS No. : 161147-59-7

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg Get quote
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

PADRE peptide Related Antibodies

Top Publications Citing Use of Products

View All MHC Isoform Specific Products:

View All Isoforms
MHC I MHC II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer[1][2][3].

In Vivo

Co-administration of PADRE peptide (100 μg per mouse; s.c.; twice with 1-week interval) with CRT-E7 DNA increases PADRE-specific CD4+ T cell counts to 41 per 3×105 splenocytes in C57BL/6 mice but does not enhance E7-specific CD8+ T cell responses[1].
PADRE peptide (20 μg/mouse; s.c.; 2 doses 1 week apart) as a separate mixture with E7 peptide and poly(I:C) induces significantly higher E7-specific CD8+ T cell responses in healthy C57BL/6 mice compared to an E7-PADRE fusion peptide formulation (p=0.019), while also enhancing PADRE-specific CD4+ T cell responses compared to single-peptide vaccination (p < 0.05)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (6-8 weeks old; HPV-16 E6-expressing carcinoma model)[1]
Dosage: 100 µg per mouse
Administration: s.c.; twice with 1-week interval; co-administered with CRT-E7 DNA (2 µg per mouse, i.d. via gene gun) on same schedule
Result: Generated 41 PADRE-specific CD4+ T cells per 3×105 splenocytes.
Did not significantly increase the number of E7-specific CD8+ T cells compared to CRT-E7 DNA plus adjuvant alone.\nGenerated a similar number of E7-specific CD8+ T cells compared to CRT-E7 DNA plus adjuvant alone.
Generated significantly fewer E7-specific CD8+ T cells than CRT-E7 DNA plus Ii-PADRE DNA.
Animal Model: C57BL/6 (female, 5-8 weeks old)[3]
Dosage: 20 μg/mouse (in combination with HPV-16 E7 (aa 49-57) peptide 20 μg/mouse and poly(I:C) 20 μg/mouse)
Administration: s.c.; 2 doses 1 week apart
Result: Generated a significantly higher number of E7-specific IFN-γ-secreting CD8+ T cells (260 per 3×105 splenocytes) compared to mice vaccinated with E7 peptide alone or PADRE peptide alone.
Generated a significantly higher number of PADRE-specific IFN-γ-secreting CD4+ T cells (749 per 3×105 splenocytes) compared to mice vaccinated with E7 peptide alone or PADRE peptide alone.
Generated significantly more E7-specific IFN-γ-secreting CD8+ T cells compared to an E7-PADRE fusion peptide (with poly(I:C)), though fewer PADRE-specific IFN-γ-secreting CD4+ T cells.
Showed equivalent memory E7-specific CD8+ T cell and PADRE-specific CD4+ T cell counts at 5 weeks post-final vaccination compared to the E7-PADRE fusion peptide group.
Molecular Weight

1347.60

Formula

C65H102N16O15
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Ala-Lys-Phe-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-Ala
Sequence Shortening

AKFVAAWTLKAAA
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 2 mg/mL (1.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.7421 mL 3.7103 mL 7.4206 mL
5 mM --- --- ---
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.2 mg/mL (0.15 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.2 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 0.2 mg/mL (0.15 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.2 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.7421 mL 3.7103 mL 7.4206 mL 18.5515 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PADRE peptide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PADRE peptide161147-59-7CD74MHCHLA-DR-gammaInvariant polypeptide of major histocompatibility complex, class II antigen-associatedMajor Histocompatibility ComplexCD4+ T cellsC57BL/6 miceI-AbHPV-16 E6/E7-expressing tumorCD8+ T cellsglioblastomaintracranial glioma modelsMHC class II moleculesHLA-DRTC-1 tumorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PADRE peptide
Cat. No.:
HY-P11303
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.